

### Disubstituted Levendustin A Analogs (Including Adaphostin) and Pharmaceutical Compositions Comprising the Analogs

Venkatacha L. Narayanan et al. (NCI)  
U.S. Patent Application No. 09/623,000  
filed 25 Aug 2000 (DHHS Reference  
No. E-013-1998/0-US-07)

*Licensing Contact:* John Stansberry;  
(301) 435-5236;  
stansbej@mail.nih.gov.

Chronic myelogenous leukemia (CML) is almost universally associated with a translocation that juxtaposes the Bcr and Abl genes. Because the resulting kinase, p210<sup>Bcr/Abl</sup>, is found exclusively in malignant hematopoietic cells there has been considerable interest in identifying inhibitors of this enzyme. Adaphostin induces cytotoxicity in human leukemia cells by down-regulating p210<sup>Bcr/Abl</sup>, inducing DNA damage and initiating apoptosis. Adaphostin exhibits selectivity for CML myeloid progenitors in vitro and retained its catholocity when cytotoxicity mesylate-resistant K562 cells were examined. Adaphostin may kill a wide range of human leukemia cells and may be effective against other cancer types. The present invention provides pharmaceutical compositions comprising effective amounts of adaphostin. The compound and composition of the present invention may be used for treating human leukemia and other proliferative diseases.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

### Heterologous Boosting Immunizations

Ronald S. Chamberlain et al. (NCI)  
U.S. Patent Application No. 09/171,086  
filed 22 Jan 1999 (HHS Reference No.  
E-087-1996/0-US-04); U.S. Patent  
Application No. 09/838,987 filed 20  
Apr 2001 (HHS Reference No. E-087-  
1996/0-US-05); U.S. Patent  
Application No. 11/007,115 filed 08  
Dec 2004 (HHS Reference No. E-087-  
1996/0-US-06); PCT Application No.  
PCT/US97/06632 filed 21 Apr 1997,  
which published as WO 97/39771 on  
30 Oct 1997 (HHS Reference No. E-  
087-1996/0-PCT-02); and Canadian  
Patent Application Serial No.  
2,252,406 (HHS Reference No. E-087-  
1996/0-CA-03)

*Licensing Contact:* Michelle A. Booden;  
301/451-7337;  
boodenm@mail.nih.gov.

The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled

the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, Dr. Steve Rosenberg and colleagues at the NCI have developed treatment regimens that use two different vectors (*i.e.*, heterologous boosting).

The present invention describes the method of heterologous boosting immunizations, which in essence is the use of a priming vaccination and a boosting vaccination using two different recombinant vectors that contain a similar or different tumor associated antigen (TAA). The use of different recombinant vectors unexpectedly increases and maintains the immune response to most tumor-associated antigens included in the vectors. The claims are directed, but not limited to, various recombinant viral vectors: poxvirus, vaccine, adenovirus, etc. Additional embodiments and claims are directed, but not limited to, melanoma tumor antigens such as Mart1, gp100, or Hep B surface antigen. These tumor antigen expressing recombinant vectors are coupled with distinctly different recombinant vectors, which express various cytokines and co-stimulatory and accessory molecules such as B7-1, B7-2, ICAM-1, etc. This therapeutic intervention could be directed toward multiple human carcinomas but, with respect to this technology, has been customized as a therapeutic intervention for melanoma.

This technology is available under an exclusive or non-exclusive license. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Dated: September 2, 2005.

#### Steven M. Ferguson,

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-18168 Filed 9-13-05; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel, Clinical Science.

*Date:* October 20-21, 2005.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Park Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Jeanette M. Hosseini, Scientific Review Administrator, National Center For Complementary and Alternative Medicine, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301-594-9096.

Dated: September 6, 2005.

#### Anthony M. Coelho, Jr.,

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-18171 Filed 9-13-05; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Library of Medicine; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the tenth and final meeting of the Commission on Systemic Interoperability.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The mission of the Commission on Systemic Interoperability is to submit a report to the Secretary of Health and Human Services and to Congress on a comprehensive strategy for the adoption and implementation of health care information technology standards that includes a timeline and prioritization for such adoption and implementation. In developing that strategy, the

Commission will consider: (1) The costs and benefits of the standards, both financial impact and quality improvement; (2) The current demand on industry resources to implement the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and other electronic standards, including HIPAA standards; and (3) The most cost-effective and efficient means for industry to implement the standards.

*Name of Committee:* Commission on Systemic Interoperability.

*Date:* October 25, 2005.

*Time:* 10:30 a.m. to 5 p.m.

*Agenda:* Healthcare Information Technology Standards.

*Place:* Hart Senate Office Building, Room 216, Constitution Avenue, Washington, DC 20510.

*Contact Person:* Ms. Dana Haza, Director, Commission on Systemic Interoperability, National Library of Medicine, National Institutes of Health, Building 38, Room 2N21, Bethesda, MD 20894, 301-594-7520, [hazad@mail.nih.gov](mailto:hazad@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The comments should include the name, address, telephone number, and when applicable, the business or professional affiliation of the interested person.

Dated: September 2, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-18170 Filed 9-13-05; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Oncological Sciences Integrated Review Group, Cancer Etiology Study Section.

*Date:* October 2-4, 2005.

*Time:* 5 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD 20814.

*Contact Person:* Victor A. Fung, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6178, MSC 7804, Bethesda, MD 20892, 301-435-3504, [fungv@csr.nih.gov](mailto:fungv@csr.nih.gov).

*Name of Committee:* Integrative, Functional and Cognitive Neuroscience Integrated Review Group, Cognitive Neuroscience Study Section.

*Date:* October 3-4, 2005.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Michael A. Steinmetz, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5172, MSC 7844, Bethesda, MD 20892, 301-435-1247, [steinmem@csr.nih.gov](mailto:steinmem@csr.nih.gov).

*Name of Committee:* Renal and Urological Studies Integrated Review Group, Urologic and Kidney Development and Genitourinary Diseases Study Section.

*Date:* October 3-4, 2005.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* M. Chris Langub, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4112, MSC 7814, Bethesda, MD 20892, 301-496-8551, [langubm@csr.nih.gov](mailto:langubm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, PAR-04-023: Bioengineering Research Partnerships.

*Date:* October 3, 2005.

*Time:* 9 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036.

*Contact Person:* Behrouz Shabestari, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, MSC 7854, Bethesda, MD 20892, (301) 435-2409, [shabestb@csr.nih.gov](mailto:shabestb@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bioengineering: Digestive Sciences.

*Date:* October 3, 2005.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Najma Begum, PhD, Scientific Review Administrator, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2175, MSC 7818, Bethesda, MD 20892, (301) 435-1243, [begumn@csr.nih.gov](mailto:begumn@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Visual Mechanisms.

*Date:* October 3, 2005.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Christine L. Melchior, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5176, MSC 7844, Bethesda, MD 20892, (301) 435-1713, [melchioc@csr.nih.gov](mailto:melchioc@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Radiation Physics.

*Date:* October 4, 2005.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Syed M. Quadri, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6210, MSC 7804, Bethesda, MD 20892, (301) 435-1211, [quadris@csr.nih.gov](mailto:quadris@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Respiratory Sciences Member Conflicts.

*Date:* October 5, 2005.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Ghenima Dirami, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2159, MSC 7818, Bethesda, MD 20892, (301) 594-1321, [diramig@csr.nih.gov](mailto:diramig@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Ion Channels and Connexins.

*Date:* October 5, 2005.

*Time:* 1 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Raya Mandler, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, (301) 402-8228, [rayam@csr.nih.gov](mailto:rayam@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Member Conflict: Biomedical Imaging Technology and Medical Imaging.

*Date:* October 5, 2005.

*Time:* 3 p.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.